Cited by 322Protease and Inhibitor MechanismsBlood Coagulation and Thrombosis MechanismsTGF-β signaling in diseases

The DOI matches its Crossref record; 494 of the 494 references it cites were found in a registry or an index.

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

Ulisse, Salvatore, Baldini, Enke, Sorrenti, Salvatore, D'Armiento, Massimino·2009·Current Cancer Drug Targets

Open this paper in CoChat — free account

Abstract

The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological processes requiring basement membrane (BM) and/or extracellular matrix (ECM) remodelling, including tumor progression and metastasis. Data accumulated over the past years have made increasingly clear that the uPAS has a multifunctional task in the neoplastic evolution, affecting tumor angiogenesis, malignant cell proliferation, adhesion and migration, intravasation and growth at the metastatic site. In agreement with their role in cancer progression and metastasis, an increased expression of uPA, uPAR, and PAI-1 has been documented in several malignant tumors, and a positive correlation between the levels of one or more uPAS members and a poor prognosis has been frequently reported. This is particularly evident in breast cancer, for which uPA has been demonstrated to be the most potent independent prognostic factor described to date. The involvement of the uPAS in cancer progression identifies its components as suitable targets for anti-cancer therapy. Several therapeutical approaches aimed at inhibiting the uPA/uPAR functions have been shown to possess anti-tumor effects in xenograft models, including selective inhibitors of uPA activity, antagonist peptides, monoclonal antibodies able to prevent uPA binding to uPAR and gene therapy techniques silencing uPA/uPAR expression. All these strategies, however, although promising, need definitive confirmation in humans as, up to now, only few uPA inhibitors entered clinical trial.

Integrity signals

Registry

Crossref · 10.2174/156800909787314002

Cites

494 of 494 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 retracted

Items 401–494 of 494

Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma
Dreicer, R., Smith, D. C., Williams, R. D., & See, W. A. (1999) · Investigational New Drugs · doi:10.1023/a:1006331518952 · Cited by 28
Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study
Zhu, G.-G., Stenbäck, F., Risteli, L., Risteli, J., & Kauppila, A. (1993) · Cancer · doi:10.1002/1097-0142(19930901)72:5 · Cited by 28
Nutraceutical inhibitors of urokinase: Potential applications in prostate cancer prevention and treatment
Jankun, J., Selman, S. H., Anioła, J., & Skrzypczak‐Jankun, E. (2006) · Oncology Reports · doi:10.3892/or.16.2.341 · Cited by 28
Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
Tamura, S. Y., Weinhouse, M. I., Roberts, C. A., Goldman, E. A., Masukawa, K. M., Anderson, S. M., Cohen, C. R., Bradbury, A. E., Bernardino, V., Dixon, S. A., et al. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00149-9 · Cited by 28
Report from the International Union Against Cancer (UICC) Tumor Biology Committee
Salgaller, M. L., Thurnher, M., Bartsch, G. H., Boynton, A. L., & Murphy, G. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991215)86:12 · Cited by 28
Prognostic Significance of the Combined Expression of Matrix Metalloproteinase-9, Urokinase Type Plasminogen Activator and its Receptor in Breast Cancer as Measured by Northern Blot Analysis
Pacheco, M. M., Nishimoto, I. N., Neto, M. M., Mantovani, E., & Brentani, M. M. (2001) · The International Journal of Biological Markers · doi:10.1177/172460080101600109 · Cited by 28
The p75NTR neurotrophin receptor is a tumor suppressor in human and murine retinoblastoma development
Dimaras, H., & Gallie, B. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23356 · Cited by 27
Tobacco Smoke Induces Urokinase-Type Plasminogen Activator and Cell Invasiveness: Evidence for an Epidermal Growth Factor Receptor–Dependent Mechanism
Du, B., Leung, H. T., Khan, K. M. F., Miller, C. G., Subbaramaiah, K., Falcone, D. J., & Dannenberg, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1388 · Cited by 27
Plasminogen activation in human acute leukaemias
Angelillo‐Scherrer, A., Wohlwend, A., Kruithof, E. K. O., Vassalli, J. D., & Sappino, A. P. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01432.x · Cited by 26
Plasminogen activator inhibitor type‐2 (PAI‐2) gene transcription requires a novel NF‐κB‐like transcriptional regulatory motif
Mahony, D., Kalionis, B., & Antalis, T. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00552.x · Cited by 26
Molecular Mechanisms Governing Tumor‐Necrosis‐Factor‐Mediated Regulation of Plasminogen‐Activator Inhibitor Type‐2 Gene Expression
Dear, A. E., Shen, Y., Rüegg, M., & Medcalf, R. L. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.0093t.x · Cited by 26
Expression of Urokinase-Type Plasminogen Activator Receptor (uPAR) in Primary Central Nervous System Neoplasms
Salajegheh, M. K., Rudnicki, A., & Smith, T. W. (2005) · Applied Immunohistochemistry · doi:10.1097/01.pai.0000138448.85231.da · Cited by 26
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
Bruncko, M., McClellan, W. J., Wendt, M. D., Sauer, D. R., Geyer, A. G., Dalton, C. R., Kaminski, M., Weitzberg, M., Gong, J., Dellaria, J. F., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.026 · Cited by 26
Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor
Han, B., Nakamura, M., Zhou, G., Ishii, A., Nakamura, A., Bai, Y., Mori, I., & Kakudo, K. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.4.807 · Cited by 26
Increased Levels of Urokinase Receptor in Plasma of Head and Neck Squamous Cell Carcinoma Patients
Schmidt, F. H. M. (1999) · Acta Oto-Laryngologica · doi:10.1080/00016489950180342 · Cited by 26
Serine-578 Is a Major Phosphorylation Locus in Human Plasma Plasminogen
Wang, H., Prorok, M., Bretthauer, R. K., & Castellino, F. (1997) · Biochemistry · doi:10.1021/bi970328d · Cited by 25
4-Amidinobenzylamine-Based inhibitors of urokinase
Künzel, S., Schweinitz, A., Reißmann, S., Stürzebecher, J., & Steinmetzer, T. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00815-0 · Cited by 25
Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface
Gerspach, J., Németh, J., Münkel, S., Wajant, H., & Pfizenmaier, K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0162-6 · Cited by 25
Molecular prognostic factors in patients with pancreatic cancer
Tonini, G., Pantano, F., Vincenzi, B., Gabbrielli, A., Coppola, R., & Santini, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1553 · Cited by 25
Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study
Herceg, G. H., Herceg, D., Kralik, M., Bence-Žigman, Z., Tomić-Brzac, H., & Kulić, A. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0703-1 · Cited by 24
Computer-assisted Mutagenesis of Ecotin to Engineer Its Secondary Binding Site for Urokinase Inhibition
Laboissière, M. C. A., Young, M. M., Pinho, R. G., Todd, S., Fletterick, R. J., Kuntz, I. D., & Craik, C. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203076200 · Cited by 24
4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
Spencer, J. R., McGee, D. P. C., Allen, D. A., Katz, B. A., Luong, C., Sendzik, M., Squires, N., & Mackman, R. L. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00312-8 · Cited by 24
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin
Ellis, V., & Danø, K. (1993) · Biochemical Journal · doi:10.1042/bj2960505 · Cited by 24
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Ito, Y., Takeda, T., Kobayashi, T., Wakasugi, E., Tamaki, Y., Umeshita, K., Monden, T., Shimano, T., & Monden, M. (1996) · PubMed · Cited by 24
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration
Riisbro, R., Christensen, I. J., Nielsen, H. J., et al. (2005) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.5473 · Cited by 23
A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients
Gradishar, W. J., Soff, G. A., Liu, J., Cisneros, A., French, S. L., RADEMAKER, A. W., Benson, A. B., & Bouck, N. (2000) · Oncology · doi:10.1159/000012120 · Cited by 23
Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Torzewski, M., Sarbia, M., Verreet, P. R., Dutkowski, P., Heep, H., Willers, R., & Gabbert, H. E. (1997) · PubMed · Cited by 23
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo, D. V., Keohane, M. E., & McKeever, P. E. (1994) · PubMed · Cited by 23
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
Heynekamp, J. J., Hunsaker, L. A., Jagt, T. A. V., Deck, L. M., & Jagt, D. L. V. (2006) · BMC Chemical Biology · doi:10.1186/1472-6769-6-1 · Cited by 22
Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor
Hu, X., Duan, H., Duan, H., Pan, S.-Y., Li, Y.-M., Xi, Y., Zhao, S.-R., Yin, L., Li, J., Chen, H., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5643 · Cited by 22
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells
Skogseth, H., LARSSON, E., & Halgunset, J. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_113504.x · Cited by 22
Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
Mohanam, S., Go, Y., Sawaya, R. A., Venkaiah, B., Mohan, P. M., Kouraklis, G. P., Gokaslan, Z. L., Lagos, G., & Rao, J. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.1.169 · Cited by 21
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx
Parolini, S., Flagiello, D., Cinquetti, A., Gozzi, R., Cristini, S., Cappiello, J., Nicolai, P., Rusnati, M., Presta, M., & Molinari-Tosatti, M. P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.512 · Cited by 21
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Volm, M., Mattern, J., & Koomägi, R. (1999) · Oncology Reports · doi:10.3892/or.6.3.611 · Cited by 21
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target
Lee, K. H., Choi, E. Y., Hyun, M. S., Jang, B. I., Kim, T. N., Lee, H. J., Eun, J. Y., Kim, H. G., Yoon, S. S., Lee, D. S., et al. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9106-6 · Cited by 20
Inhibition of Intraperitoneal Tumor Growth of Human Ovarian Cancer Cells by Bi- and Trifunctional Inhibitors of Tumor-Associated Proteolytic Systems
Krol, J., Kopitz, C., Kirschenhofer, A., Schmitt, M., Magdolen, U., Krüger, A., & Magdolen, V. (2003) · Biological Chemistry · doi:10.1515/bc.2003.122 · Cited by 20
Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator
Yang, S. Q., & Craik, C. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1749 · Cited by 20
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer
Försti, A., Lei, H., Tavelin, B., Enquist, K., Palmqvist, R., Altieri, A., Hallmans, G., Hemminki, K., & Lenner, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm361 · Cited by 20
uPA receptor expression in benign and malignant thyroid tumors.
Kim, S. J., Shiba, E., Taguchi, T., Tsukamoto, F., Miyoshi, Y., Tanji, Y., Takai, S., & Noguchi, S. (2002) · PubMed · Cited by 20
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Štabuc, B., Markovič, J., Bartenjev, I., Vrhovec, I., Medved, U., & Kocijančič, B. (2003) · PubMed · Cited by 19
Properties of Metastasizing and Nonmetastasizing Human Melanoma Cells
van Muijen, G. N. P., Danen, E. H. J., de Vries, T. J., Quax, P. H. A., Verheijen, J. H., & Ruiter, D. J. (1995) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-78771-3_8 · Cited by 19
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase
Skogseth, H., LARSSON, E., & Halgunset, J. (2006) · Apmis · doi:10.1111/j.1600-0463.2006.apm_230.x · Cited by 19
Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection
D’Amico, T. A., Brooks, K. R., Joshi, M.-B. M., Conlon, D. H., Herndon, J. E., Petersen, R. P., & Harpole, D. H. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.01.042 · Cited by 19
Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma
El-kott, A. F., Khalil, A., & El-Kenawy, A. E.-M. (2004) · International Urology and Nephrology · doi:10.1007/s11255-004-8684-3 · Cited by 19
Expression and localisation of urokinase-type plasminogen activator gene in gliomas
Zhang, X., Bu, X., Zhen, H., Fei, Z., Zhang, J.-N., & Fu, L. (2000) · Journal of Clinical Neuroscience · doi:10.1054/jocn.1999.0161 · Cited by 19
A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number.
Szende, B., Okada, Y., Tsuda, Y., Horváth, A., Bökönyi, G., Okamoto, S., Wanaka, K., & Kéri, G. (2002) · PubMed · Cited by 19
Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor)
Li, C. F., Kandel, C. E., Baliko, F., Nadesan, P., Brünner, N., & Alman, B. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208193 · Cited by 18
Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells
Packman, K. S., Demeure, M. J., Doffek, K. M., & Wilson, S. D. (1995) · Surgery · doi:10.1016/s0039-6060(05)80107-2 · Cited by 18
Interleukin‐6‐induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein β (C/EBPβ)
Bannach, F. G., Gutiérrez‐Fernández, A., Parmer, R. J., & Miles, L. A. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01022.x · Cited by 18
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma
Bhuvarahamurthy, V., Schroeder, J., Kristiansen, G., Roigas, J., Denkert, C., Johannsen, M., Lein, M., Loening, S. A., Schnorr, D., Jung, K., et al. (2005) · Oncology Reports · doi:10.3892/or.14.3.777 · Cited by 17
cDNA Transfection of Amino-Terminal Fragment of Urokinase Efficiently Inhibits Cancer Cell Invasion and Metastasis
Zhu, F.-X., Jia, S., Xing, G., Gao, L., Zhang, L., & He, F. (2001) · DNA and Cell Biology · doi:10.1089/104454901750232490 · Cited by 17
Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells
Mustjoki, S. M., Tapiovaara, H., Sirén, V., & Vaheri, A. I. (1998) · Leukemia · doi:10.1038/sj.leu.2400918 · Cited by 17
Localization of the human α 2 -plasmin inhibitor gene (PLI) to 17p13
Kato, A., Hirosawa, S., Toyota, S., Nakamura, Y., Nishi, H., Kimura, A., Sasazuki, T., & Aoki, N. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000133472 · Cited by 17
The p75NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells
Nalbandian, A., & Djakiew, D. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9009-y · Cited by 17
Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
Ljuca, D., Fatušić, Z., Iljazović, E., & Ahmetović, B. (2007) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2007.3063 · Cited by 17
Clinical relevance of urokinase‐type plasminogen activator and its inhibitor type 1 (PAI‐1) in squamous cell carcinoma of the uterine cervix
Horn, L., Pippig, S. D., Raptis, G., Fischer, U., Köhler, U., Hentschel, B., & Martín, R. (2002) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.0004-8666.2002.00385.x · Cited by 16
Induction of Apoptosis of Osteoclasts by Targeting Transcription Factors with Decoy Molecules
Piva, R., Penolazzi, L., Zennaro, M., Bianchini, E., Magri, E., Borgatti, M., Lampronti, I., Lambertini, E., Tavanti, E., & Gambari, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.092 · Cited by 16
Molecular regulation of an invasion-related molecule – options for tumour staging and clinical strategies
Allgayer, H. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.018 · Cited by 16
Role of β3-endonexin in the regulation of NF-κB-dependent expression of urokinase-type plasminogen activator receptor
Besta, F., Maßberg, S., Brand, K., Müller, E., Page, S., Grüner, S., Lorenz, M., Sadoul, K., Kolanus, W., Lengyel, E. R., et al. (2002) · Journal of Cell Science · doi:10.1242/jcs.00081 · Cited by 15
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak, M., Babić, D., Abramić, M., Miličić, D., Vrhovec, I., & Skrk, J. (2001) · PubMed · Cited by 15
Structure-Based design, synthesis and sAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors
Subasinghe, N. L., Illig, C. R., Hoffman, J. B., Rudolph, M. J., Wilson, K. J., Söll, R., Randle, T. L., Green, D. J., Lewandowski, F. A., Zhang, M., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00247-5 · Cited by 14
Plasminogen gene expression is regulated by nerve growth factor
Gutiérrez‐Fernández, A., Parmer, R. J., & Miles, L. A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02636.x · Cited by 14
The Independence of Signaling Pathways Mediating Increased Expression of Plasminogen Activator Inhibitor Type 1 in HepG2 Cells Exposed to Free Fatty Acids or Triglycerides
Chen, Y., & Schneider, D. J. (2001) · Journal of Diabetes Research · doi:10.1080/15604280214488 · Cited by 14
Calcitonin stimulates the secretion of urokinase‐type plasminogen activator from prostate cancer cells: Its possible implications on tumor cell invasion
Sabbisetti, V. S., Chigurupati, S., Thomas, S., & Shah, G. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.21625 · Cited by 13
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii, T., Yabe, H., Morioka, H., Yamada, R., Nakagawa, T., & Toyama, Y. (2000) · PubMed · Cited by 13
A Bisanthracycline (WP631) Represses uPAR Gene Expression and Cell Migration of RKO Colon Cancer Cells by Interfering With Transcription Factor Binding to a Chromatin-Accessible −148/−124 Promoter Region
Nair, R. R., Wang, H., Jamaluddin, M. S., Fokt, I., Priebe, W., & Boyd, D. D. (2005) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504005776404571 · Cited by 13
Plasminogen activator in acute myeloid leukaemic marrows: u‐PA in contrast to t‐PA in normal marrow
McWilliam, N. A., ROBBIE, L. A., Booth, N. A., & Bennett, B. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00762.x · Cited by 12
Marked regression of liver metastasis by combined therapy of ultrasound‐mediated NFkB‐decoy transfer and transportal injection of paclitaxel, in mouse
Azuma, H., Tomita, N., Sakamoto, T., Kiyama, S., Inamoto, T., Takahara, K., Kotake, Y., Segawa, N., Morishita, R., Takahara, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23280 · Cited by 12
Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression
Wang, H., Yan, C., Asangani, I. A., Allgayer, H., & Boyd, D. B. (2006) · Oncogene · doi:10.1038/sj.onc.1210003 · Cited by 11
Specific conformational changes of plasminogen induced by chloride ions, 6-aminohexanoic acid and benzamidine, but not the overall openness of plasminogen regulate, production of biologically active angiostatins
Warejcka, D. J., & Twining, S. S. (2005) · Biochemical Journal · doi:10.1042/bj20050907 · Cited by 10
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey, S. J., Marsh, N. A., Ray, M., Butler, D. R., Dare, A. J., & Hawson, G. A. T. (1996) · PubMed · Cited by 10
Role of carbohydrate on angiostatin in the treatment of cancer
Pirie-Shepherd, S. R. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90093-8 · Cited by 9
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer].
Żekanowska, E., Cieśliński, K., & Rość, D. (2004) · PubMed · Cited by 9
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai, Z., Li, Y., Liu, F., Feng, Y., Hou, J., & Zhao, M. (2007) · PubMed · Cited by 9
Significance of plasminogen-activation system in the formation of macroscopic types and invasion in esophageal carcinoma.
Nomiya, T., Nemoto, K., Miyachi, H., Fujimoto, K., Takahashi, C., Takeda, K., Matusita, H., Ogawa, Y., Takai, Y., & Yamada, S. (2002) · PubMed · Cited by 8
Serine proteinase activation in esophageal cancer.
Tang, W. H., Friess, H., Kekis, P. B., Me, M., Fukuda, A., Roggo, A., Zimmerman, A., & Mw, B. (2001) · PubMed · Cited by 8
Plasminogen Activators and Their Inhibitor in Bone Tumors and Tumor-Like Damages
Кушлинский, Н. Е., Yusifov, A. I., Герштейн, Е. С., Solov’ev, Y. N., & Трапезников, Н. Н. (2001) · Bulletin of Experimental Biology and Medicine · doi:10.1023/a:1013046432016 · Cited by 7
Molecular Genetics of Alpha 2 Plasmin Inhibitor
Aoki, N. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-3806-6_19 · Cited by 7
Myeloid leukaemic cells can lyse fibrin directly
ROBBIE, L. A., Berry, S., Moir, E., Booth, N. A., Culligan, D. J., Tighe, J. E., Watson, H. G., King, D. J., & Bennett, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02381.x · Cited by 7
Plasma Urokinase-Type Plasminogen Activator in Patients with Leukemias
Wada, K., Takahashi, H., Hanano, M., Tatewaki, W., Niwano, H., Seki, Y., & Shibata, A. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409049754 · Cited by 7
Celecoxib Inhibits Urokinase-Type Plasminogen Activator (uPA) Production in MDA-MB-231 Breast Cancer Cells
Andrews, H. N., Habibi, G., Kucab, J. E., & Dunn, S. E. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6941-5 · Cited by 7
Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Sauer, G., Kurzeder, C., Heilmann, H., Kreienberg, R., & Deissler, H. L. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414547 · Cited by 7
Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.
Datta, A., Kitson, R. P., Xue, Y., Alatrash, G., Mazar, A. P., Jones, T. R., & Goldfarb, R. H. (2002) · PubMed · Cited by 6
[Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou, Q., Liang, L., Peng, B., & Zhen, Y.-Y. (2006) · PubMed · Cited by 6
A research shortcut from a common cold virus to human cancer
Harlow, E. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960801)78:3 · Cited by 5
An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients
Li, C. F., Wei, R. Y., Baliko, F., Bapat, B. V., & Alman, B. A. (2006) · Familial Cancer · doi:10.1007/s10689-006-9109-5 · Cited by 5
Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors
Skogseth, H., LARSSON, E., & Halgunset, J. (2006) · Apmis · doi:10.1111/j.1600-0463.2006.apm_248.x · Cited by 5
PAI-1 expression levels in esophageal and colorectal cancers are closely correlated to those in corresponding normal tissues.
Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K., & Nakao, A. (2006) · PubMed · Cited by 5
Differential Expression Levels of Urokinase-Type Plasminogen Activator and Cathepsin D in Locally Advanced Laryngeal Squamous Cell Carcinoma: Clinical Implications
Leto, G., Tumminello, F. M., Gebbia, V., Bazan, V., Tomasino, R. M., Dardanoni, G., & Russo, A. D. (2001) · The International Journal of Biological Markers · doi:10.1177/172460080101600404 · Cited by 5
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases].
Кушлинский, Н. Е., Герштейн, Е. С., Казанцева, И. А., Kharitidi, T. I., Lt, L., Казаков, С. П., Bagatyrev, O. P., & Калинин, А. П. (2001) · PubMed · Cited by 4
The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients
Yılmaz, M. B., Dağdaş, S., Akı, Ş. Z., Güler, N., Aköz, A., Erdin, Z., Alanoğlu, G., & Özet, G. (2006) · Clinical & Laboratory Haematology · doi:10.1111/j.1365-2257.2006.00820.x · Cited by 3
[Influence of nuclear factor-kappaB decoy transfection on nuclear factor-kappaB activity and vascular endothelial growth factor/urokinase-type plasminogen activator/intercellular cell adhesion molecule-1 level of SKOV3 cells].
Lu, J., Sun, H., Cao, C., & Ou, Z.-L. (2004) · PubMed · Cited by 3
Untitled work
Wooten (1993) · doi:10.1002/1097-0142(19931201)72:11
Untitled work
(2001) · doi:10.1002/1098-1128(200103)21:2

Flagged first, then by citations

Sorted by citations

Diabetes and Cancer
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
Mucha, A., Kafarski, P. K., & Berlicki, Ł. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200587f · Cited by 679
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets
Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 494

See all 322

Authors: Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M.
Affiliations: Sapienza University of Rome (IT)
ORCID: Ulisse, Salvatore
Baldini, Enke
Sorrenti, Salvatore
Venue: Current Cancer Drug Targets
Publisher: Bentham Science Publishers Ltd.
Published: 2009-02-01
Volume: 9
Issue: 1
Pages: 32-71
ISSN: 1568-0096 (ISSN-L)
DOI: 10.2174/156800909787314002
OpenAlex: W2135351121
Cited by: 312
References: 493
Citations by year: 2026: 6 · 2025: 6 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 18 · 2020: 14 · 2019: 16 · 2018: 16 · 2017: 17 · 2016: 17 · 2015: 23 · 2014: 33 · 2013: 31 · 2012: 25
FWCI: 9.37
Type: journal article
Language: en
Open access: closed
Locations: Current Cancer Drug Targets (publishedVersion)
PubMed (publishedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords: urokinase, urokinase receptor, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, plasmin, extracellular matrix remodeling, metastasis, tumor progression, tumor angiogenesis, breast cancer, prognostic factors, cancer therapy, uPA inhibitors, monoclonal antibodies, gene therapy, xenograft models
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Urokinase-Type Plasminogen Activator

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks